On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...
On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...